Who is sponsoring NCT05118230?

NCT05118230 is sponsored by Novartis Pharmaceuticals.

What condition does NCT05118230 study?

NCT05118230 studies Primary Hypercholesterolemia, Mixed Dyslipidemia.

What is the status of NCT05118230?

NCT05118230 is currently COMPLETED.

Last reviewed 2024-08-07 · How we verify

Study to Assess the Real World Effectiveness of Inclisiran in Chinese Adult Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

NCT05118230 COMPLETED

This is a multi-center, prospective, comparative and non-interventional cohort study involving two cohorts, one cohort (Inclisiran Cohort) of patients treated with inclisiran in certain special territories in China (eg. Bo'ao Pilot Zone) and the other cohort (SoC Historical Cohort) of patients treated with standard of care (SoC) in routine clinical practice from EMR database.

Details

Lead sponsor	Novartis Pharmaceuticals
Status	COMPLETED
Enrolment	61
Start date	Thu Dec 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat Jul 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Primary Hypercholesterolemia
Mixed Dyslipidemia

Interventions

Inclisiran

Countries

China